Caladrius Biosciences (NASDAQ:CLBS) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Caladrius Biosciences (NASDAQ:CLBS) from a sell rating to a hold rating in a report released on Monday, reports.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Several other brokerages have also issued reports on CLBS. Chardan Capital reaffirmed a buy rating and issued a $6.00 target price on shares of Caladrius Biosciences in a research note on Sunday, May 12th. WBB Securities initiated coverage on Caladrius Biosciences in a research note on Tuesday, May 14th. They issued a speculative buy rating and a $6.75 target price for the company. Finally, ValuEngine lowered Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Caladrius Biosciences has an average rating of Buy and an average price target of $9.25.

Shares of CLBS stock traded down $0.06 during trading on Monday, hitting $2.60. The company had a trading volume of 8,800 shares, compared to its average volume of 34,499. The business’s 50-day simple moving average is $2.71. Caladrius Biosciences has a 52 week low of $2.16 and a 52 week high of $6.83.

Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.05). Equities analysts anticipate that Caladrius Biosciences will post -1.66 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Caladrius Biosciences stock. Wesbanco Bank Inc. acquired a new stake in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $36,000. Wesbanco Bank Inc. owned 0.10% of Caladrius Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 7.59% of the company’s stock.

About Caladrius Biosciences

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Story: How to invest in blue-chip stocks

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.